Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 165,975	$ 154,901
Marketable securities	256,923	236,949
Accounts receivable, net of reserves of $4,783 in 2017 and $4,523 in 2016	240,262	204,494
Inventories	169,693	158,034
Other current assets	85,805	91,206
Total current assets	918,658	845,584
Long-Term Assets:
Property and equipment, net	364,779	357,422
Goodwill	196,670	178,228
Intangible assets, net	46,089	46,155
Other long-term assets	110,941	103,315
Total long-term assets	718,479	685,120
TOTAL ASSETS	1,637,137	1,530,704
Current Liabilities:
Accounts payable	58,606	60,057
Accrued liabilities	210,181	236,131
Line of credit	704,000	611,000
Current portion of deferred revenue	28,706	27,380
Total current liabilities	1,001,493	934,568
Long-Term Liabilities:
Deferred income tax liabilities	37,503	39,287
Long-term debt	600,891	593,110
Long-term deferred revenue, net of current portion	34,127	33,015
Other long-term liabilities	49,230	38,937
Total long-term liabilities	721,751	704,349
Total liabilities	1,723,244	1,638,917
Commitments and Contingencies (Note 14)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 103,951 shares in 2017 and 103,341 shares in 2016	10,395	10,334
Additional paid-in capital	1,046,473	1,011,895
Deferred stock units: Outstanding: 229 units in 2017 and 231 units in 2016	5,931	5,514
Retained earnings	694,777	540,401
Accumulated other comprehensive loss	(38,388)	(43,053)
Treasury stock, at cost: 16,504 shares in 2017 and 15,367 shares in 2016	(1,805,523)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(86,335)	(108,352)
Noncontrolling interest	228	139
Total stockholders’ deficit	(86,107)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,637,137	$ 1,530,704